Literature DB >> 33474589

Neurological features and outcomes of Wilson's disease: a single-center experience.

Bedia Samanci1, Erdi Sahin2, Basar Bilgic2, Zeynep Tufekcioglu2, Hakan Gurvit2, Murat Emre2, Kadir Demir3, Hasmet A Hanagasi2.   

Abstract

Wilson's disease (WD) is an autosomal recessive genetic disorder of copper metabolism, and WD patients can present with neurologic symptoms. We aimed to report the general characteristics and prognosis of a Turkish series of WD patients with neurological manifestations. A total of 12,352 patients were screened from the patient database, and 53 WD patients were included. Patients were classified based on the predominant neurological syndrome type including tremor, dystonia, parkinsonism, or discrete neurological signs and were classified as having "good outcome," "stable," and "poor outcome" according to their treatment response. There were 32 male and 21 female patients, aged 20-66 years. The mean follow-up was 11.3 ± 4.56 years. Sixty-two percent of patients presented predominantly with neurological symptoms. Neurological WD diagnosis was established after a mean time delay of 2.3 years from the WD diagnosis. The most common neurological manifestation was dystonia, followed by tremor and parkinsonism. Fifteen patients had a family history of WD. Consanguinity was present in 20 patients. Patients were treated with D-penicillamine, trientine, zinc salts, or their combinations. Besides the main treatments, 41 patients were on symptomatic treatment for neurologic symptoms. Thirty-six patients had a "good outcome," five patients were stable, and six patients had "poor outcome." Post-chelation neurological worsening was observed in 11 patients. WD should be considered in differential diagnosis in any patient with unexplained neurologic symptoms. Early diagnosis is important, and appropriate treatment should be promptly initiated to prevent progressive and irreversible damage, with good prognosis and stable disease in the majority of the patients with treatment compliance.

Entities:  

Keywords:  Neurologic; Outcome; Prognosis; Wilson’s disease

Year:  2021        PMID: 33474589     DOI: 10.1007/s10072-020-05013-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  4 in total

1.  Diagnosis and characterization of presymptomatic patients with Wilson's disease and the use of molecular genetics to aid in the diagnosis.

Authors:  V Yuzbasiyan-Gurkan; V Johnson; G J Brewer
Journal:  J Lab Clin Med       Date:  1991-11

Review 2.  Wilson's disease.

Authors:  C D Marsden
Journal:  Q J Med       Date:  1987-12

Review 3.  Wilson Disease.

Authors:  Ronald F Pfeiffer
Journal:  Continuum (Minneap Minn)       Date:  2016-08

4.  Chelation treatment of neurological Wilson's disease.

Authors:  J M Walshe; M Yealland
Journal:  Q J Med       Date:  1993-03
  4 in total
  2 in total

1.  Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study.

Authors:  Francesca Gorini; Michele Santoro; Anna Pierini; Lorena Mezzasalma; Silvia Baldacci; Elena Bargagli; Alessandra Boncristiano; Maurizia Rossana Brunetto; Paolo Cameli; Francesco Cappelli; Giancarlo Castaman; Barbara Coco; Maria Alice Donati; Renzo Guerrini; Silvia Linari; Vittoria Murro; Iacopo Olivotto; Paola Parronchi; Francesca Pochiero; Oliviero Rossi; Barbara Scappini; Andrea Sodi; Alessandro Maria Vannucchi; Alessio Coi
Journal:  Front Pharmacol       Date:  2022-05-16       Impact factor: 5.988

Review 2.  The Role of Zinc in the Treatment of Wilson's Disease.

Authors:  Abolfazl Avan; Anna Członkowska; Susan Gaskin; Alberto Granzotto; Stefano L Sensi; Tjaard U Hoogenraad
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.